Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years
Extended hormonal therapy with tamoxifen for > 5 years has improved disease-free survival (DFS) and overall survival (OS) in hormone receptor (HR)-positive breast cancer patients. The aim of this study was to identify the HR-positive breast cancer women who need adjuvant tamoxifen for > 5 year...
Main Authors: | Chiao-En Wu, Shin-Cheh Chen, Hsien-Kun Chang, Yung-Feng Lo, Swei Hsueh, Yung-Chang Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-04-01
|
Series: | Journal of the Formosan Medical Association |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S092966461500131X |
Similar Items
-
By the Metrics Surgical Oophorectomy Plus Tamoxifen is the First Adjuvant Treatment Option for Premenopausal Women with Hormone Receptor Positive Breast Cancer
by: Richard Love
Published: (2021-01-01) -
Adjuvant hormone therapy in postmenopausal patients with locally advanced breast cancer: hope and reality
by: V. I. Borisov
Published: (2014-07-01) -
Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer
by: Montagna E, et al.
Published: (2021-09-01) -
Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction? [Ist die Einnahme von Tamoxifen zum Zeitpunkt der mikrovaskulären Brustrekonstruktion mit einer erhöhten Rate an thrombembolischen Komplikationen assoziiert?]
by: Krämer, Robert, et al.
Published: (2013-02-01) -
Ten-year adjuvant hormone therapy for breast cancer: the pros and cons (a review of literature)
by: S. M. Portnoy, et al.
Published: (2014-07-01)